DermBiont, Inc., a Massachusetts-based corporation developing a skin microbiome therapeutics platform to treat and prevent various skin diseases, is one of the investees of Anitrinia Limited.
In March 2023 DermBiont announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions. Dr. Karl Beutner, Co-Founder and Chief Executive Officer of DermBiont, presented the trial results at the Late Breakers session of the American Academy of Dermatology (AAD) Annual Meeting, taking place in New Orleans, LA from March 17-21, 2023. Dr. Beutner stated that the results of this trial have defined a highly effective and well-tolerated treatment regimen. He believes that SM-020 has the potential to provide patients with a safe, easy-to-apply product to treat their SK lesions at home, meanwhile the current standard of care for treatment of patients’ SKs involves painful and destructive surgical procedures. DermBiont is planning to advance their product to a larger, vehicle-controlled trial.
